June 2026 Press Article
Encapsulation is essential for new treatments based on RNA, anticancer therapies, gene therapies, and other advanced therapeutics.
Description
Biotech One is a French company providing an advanced manufacturing solution for nanoliposomes and lipid nanoparticles (LNPs) designed for next-generation therapies.
The rapid emergence of mRNA vaccines, gene therapies, biotherapeutics, and other innovative treatments has made encapsulation a critical challenge. It plays a key role in ensuring the stability, protection, bioavailability, and efficacy of highly sensitive molecules.
To address these challenges, Biotech One has developed EncapX, a patented continuous manufacturing platform for liposomes and lipid nanoparticles (LNPs), based on an innovative supercritical CO₂ millifluidics technology. This unique approach combines the precision of microfluidics with true industrial scalability while eliminating clogging issues, reducing operating costs, and preserving the integrity of sensitive molecules through a low-temperature, solvent-free process that avoids toxic solvents.
Biotech One supports pharmaceutical, biotechnology, cosmetics, and high-value ingredient companies throughout the entire development cycle, from feasibility studies and process development to technology transfer and industrial-scale manufacturing.
The company also develops innovative supercritical CO₂ extraction and sterilization processes, contributing to cleaner, safer, and more sustainable manufacturing methods.
Our ambition is to accelerate the translation of scientific innovation into industrial applications by transforming fragile molecules into robust, stable, and scalable formulations.
Our brochures
Discover our latest offerings